Cargando…

Biliverdin Reductase-A correlates with inducible nitric oxide synthasein in atorvastatin treated aged canine brain

Alzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive impairment and neuropathology. Recent preclinical and epidemiological studies proposed statins as a possible therapeutic drug for Alzheimer's disease, but the exact mechanisms of action are still unk...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Domenico, Fabio, Perluigi, Marzia, Barone, Eugenio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145901/
https://www.ncbi.nlm.nih.gov/pubmed/25206501
http://dx.doi.org/10.3969/j.issn.1673-5374.2013.21.001
_version_ 1782332236573442048
author Di Domenico, Fabio
Perluigi, Marzia
Barone, Eugenio
author_facet Di Domenico, Fabio
Perluigi, Marzia
Barone, Eugenio
author_sort Di Domenico, Fabio
collection PubMed
description Alzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive impairment and neuropathology. Recent preclinical and epidemiological studies proposed statins as a possible therapeutic drug for Alzheimer's disease, but the exact mechanisms of action are still unknown. Biliverdin reductase-A is a pleiotropic enzyme involved in cellular stress responses. It not only transforms biliverdin-IX alpha into the antioxidant bilirubin-IX alpha but its serine/threonine/tyrosine kinase activity is able to modulate cell signaling networks. We previously reported the beneficial effects of atorvastatin treatment on biliverdin reductase-A and heme oxygenase-1 in the brains of a well characterized pre-clinical model of Alzheimer's disease, aged beagles, together with observed improvement in cognition. Here we extend our knowledge of the effects of atorvastatin on inducible nitric oxide synthase in parietal cortex, cerebellum and liver of the same animals. We demonstrated that atorvastatin treatment (80 mg/day for 14.5 months) to aged beagles selectively increased inducible nitric oxide synthase in the parietal cortex but not in the cerebellum. In contrast, inducible nitric oxide synthase protein levels were significantly decreased in the liver. Significant positive correlations were found between biliverdin reductase-A and inducible nitric oxide synthase as well as heme oxygenase-1 protein levels in the parietal cortex. The opposite was observed in the liver. Inducible nitric oxide synthase up-regulation in the parietal cortex was positively associated with improved biliverdin reductase-A functions, whereas the oxidative-induced impairment of biliverdin reductase-A in the liver negatively affected inducible nitric oxide synthase expression, thus suggesting a role for biliverdin reductase-A in atorvastatin-dependent inducible nitric oxide synthase changes. Interestingly, increased inducible nitric oxide synthase levels in the parietal cortex were not associated with higher oxidative/nitrosative stress levels. We hypothesize that biliverdin reductase-A-dependent inducible nitric oxide synthase regulation strongly contributes to the cognitive improvement observed following atorvastatin treatment.
format Online
Article
Text
id pubmed-4145901
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-41459012014-09-09 Biliverdin Reductase-A correlates with inducible nitric oxide synthasein in atorvastatin treated aged canine brain Di Domenico, Fabio Perluigi, Marzia Barone, Eugenio Neural Regen Res Research and Report Article: Neurodegenerative Disease and Neural Regeneration Alzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive impairment and neuropathology. Recent preclinical and epidemiological studies proposed statins as a possible therapeutic drug for Alzheimer's disease, but the exact mechanisms of action are still unknown. Biliverdin reductase-A is a pleiotropic enzyme involved in cellular stress responses. It not only transforms biliverdin-IX alpha into the antioxidant bilirubin-IX alpha but its serine/threonine/tyrosine kinase activity is able to modulate cell signaling networks. We previously reported the beneficial effects of atorvastatin treatment on biliverdin reductase-A and heme oxygenase-1 in the brains of a well characterized pre-clinical model of Alzheimer's disease, aged beagles, together with observed improvement in cognition. Here we extend our knowledge of the effects of atorvastatin on inducible nitric oxide synthase in parietal cortex, cerebellum and liver of the same animals. We demonstrated that atorvastatin treatment (80 mg/day for 14.5 months) to aged beagles selectively increased inducible nitric oxide synthase in the parietal cortex but not in the cerebellum. In contrast, inducible nitric oxide synthase protein levels were significantly decreased in the liver. Significant positive correlations were found between biliverdin reductase-A and inducible nitric oxide synthase as well as heme oxygenase-1 protein levels in the parietal cortex. The opposite was observed in the liver. Inducible nitric oxide synthase up-regulation in the parietal cortex was positively associated with improved biliverdin reductase-A functions, whereas the oxidative-induced impairment of biliverdin reductase-A in the liver negatively affected inducible nitric oxide synthase expression, thus suggesting a role for biliverdin reductase-A in atorvastatin-dependent inducible nitric oxide synthase changes. Interestingly, increased inducible nitric oxide synthase levels in the parietal cortex were not associated with higher oxidative/nitrosative stress levels. We hypothesize that biliverdin reductase-A-dependent inducible nitric oxide synthase regulation strongly contributes to the cognitive improvement observed following atorvastatin treatment. Medknow Publications & Media Pvt Ltd 2013-07-25 /pmc/articles/PMC4145901/ /pubmed/25206501 http://dx.doi.org/10.3969/j.issn.1673-5374.2013.21.001 Text en Copyright: © Neural Regeneration Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research and Report Article: Neurodegenerative Disease and Neural Regeneration
Di Domenico, Fabio
Perluigi, Marzia
Barone, Eugenio
Biliverdin Reductase-A correlates with inducible nitric oxide synthasein in atorvastatin treated aged canine brain
title Biliverdin Reductase-A correlates with inducible nitric oxide synthasein in atorvastatin treated aged canine brain
title_full Biliverdin Reductase-A correlates with inducible nitric oxide synthasein in atorvastatin treated aged canine brain
title_fullStr Biliverdin Reductase-A correlates with inducible nitric oxide synthasein in atorvastatin treated aged canine brain
title_full_unstemmed Biliverdin Reductase-A correlates with inducible nitric oxide synthasein in atorvastatin treated aged canine brain
title_short Biliverdin Reductase-A correlates with inducible nitric oxide synthasein in atorvastatin treated aged canine brain
title_sort biliverdin reductase-a correlates with inducible nitric oxide synthasein in atorvastatin treated aged canine brain
topic Research and Report Article: Neurodegenerative Disease and Neural Regeneration
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145901/
https://www.ncbi.nlm.nih.gov/pubmed/25206501
http://dx.doi.org/10.3969/j.issn.1673-5374.2013.21.001
work_keys_str_mv AT didomenicofabio biliverdinreductaseacorrelateswithinduciblenitricoxidesynthaseininatorvastatintreatedagedcaninebrain
AT perluigimarzia biliverdinreductaseacorrelateswithinduciblenitricoxidesynthaseininatorvastatintreatedagedcaninebrain
AT baroneeugenio biliverdinreductaseacorrelateswithinduciblenitricoxidesynthaseininatorvastatintreatedagedcaninebrain